Safe Regimen for Patients Undergoing Stem Cell Transplantation

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

Safe Regimen for Patients Undergoing Stem Cell Transplantation

header-info

Apr, 26, 2023

In a recent subanalysis from a Phase I study, a monoclonal antibody called JSP191 (briquilimab); low-dose total body radiation; and fludarabine, a novel conditioning regimen for alloHCT, were shown to be safe and well-tolerated in patients with AML and MDS. The use of briquilimab in combination with low-dose TBI and fludarabine appeared to be effective in achieving full donor myeloid chimerism and promoting engraftment of the donor cells.

Access the full article to read more here.